

Corium International, Inc.  
Form 8-K  
February 22, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of report (date of earliest event reported): February 22, 2016**

---

**Corium International, Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**001-36375**  
(Commission File Number)

**38-3230774**  
(I.R.S. Employer  
Identification Number)

**235 Constitution Drive,  
Menlo Park, California**  
(Address of Principal Executive Offices)

**94025**  
(Zip Code)

Edgar Filing: Corium International, Inc. - Form 8-K

(650) 298-8255

(Registrant's telephone number, including area code)

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01. Regulation FD.**

On February 22, 2016, Corium International, Inc. (the Company) issued a press release to announce topline interim results from a Phase 1 clinical study designed to evaluate the pharmacokinetics, safety and tolerability of the Corplex Memantine transdermal delivery system for the treatment of Alzheimer's disease. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. The Company will discuss these results further on an investor conference call scheduled at 5:00 p.m. Eastern time on February 22, 2016. A copy of the related presentation materials that the Company intends to provide to investors on the conference call are attached as Exhibit 99.2 to this report and are incorporated herein by reference. These presentation materials also will be posted under the Investors section on the Company's website at [www.coriumgroup.com](http://www.coriumgroup.com). The Company does not undertake to update these presentation materials.

The information furnished with this report, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release dated February 22, 2016.
99.2	Presentation materials for conference call on February 22, 2016.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CORIUM INTERNATIONAL, INC.**

Date: February 22, 2016

By: */s/ Peter D. Staple*  
Peter D. Staple  
Chief Executive Officer

**INDEX TO EXHIBITS**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press release dated February 22, 2016.
99.2	Presentation materials for conference call on February 22, 2016.